Bayer will present new data from the ARANOTE trial evaluating ultra-low prostate-specific antigen responses with NUBEQA ® ...

Medically reviewed by Matthew Wosnitzer, MD Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer ...

Metastatic castration-resistant prostate cancer causes urinary symptoms, fatigue, pain, and more. This article covers the ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

The widow of a stalwart WA farmer who took his life amid a battle with prostate cancer is calling on politicians to ‘stand up ...

The treatment of prostate cancer in Uganda follows similar principles to those used worldwide, including surgery, radiation ...